Mezzion’s PDE5 inhibitor enters U.S. trials for Fontan patients
SHANGHAI – Mezzion Pharma Co. Ltd., of Seoul, South Korea, has signed an agreement with New England Research Institutes Inc. (NERI) to conduct government-sponsored clinical trials for udenafil. A long-acting phosphodiesterase type 5 (PDE5) inhibitor first approved in Korea and Russia for erectile dysfunction, udenafil will be trialed as a treatment for adolescents who face shortened lifespans due to reduced heart function due to congenital heart defects.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST